Proton Radiosurgery for the Treatment of Malignant Ventricular Tachyarrhythmias
A legfontosabb adatok
- Ki végzi
- Azienda Sanitaria Universitaria Integrata del Trentino
- Hol
- Olaszország1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 21 fő, tervezett
- Kezdés
- 2025. febr.
- Várható befejezés
- 2030. febr.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Stereotactic Arrhythmia Radioablation (STAR) with Proton Therapy
- A regiszteradat frissítve
- 2025. január 27.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with an implanted defibrillator who keep having dangerous fast heart rhythms (ventricular tachycardia or fibrillation) despite medicines. It tests proton radiation aimed at the heart area causing the rhythm problem.
- Életkor
- 40 years or older.
- Nem
- All sexes can join.
- A betegség stádiuma
- At least 3 episodes of ventricular tachycardia/ventricular fibrillation in the previous 6 months that needed a shock or ATP from the device. Episodes do not respond to maximal drug therapy. Left ventricular ejection fraction (heart pumping strength) must be 20% or more.
- Korábbi kezelés
- Must have an ICD/CRT-D or S-ICD. Must be on maximal drug therapy without control. Catheter ablation is too risky, already failed or cannot be done, or the person refuses it because of high risk.
A részvétel fő kizáró okai
- Earlier chest radiotherapy that involved the heart.
- Active lack of blood flow to the heart muscle, or heart artery procedure in the last 120 days.
- Unstable circulation, such as cardiogenic shock or NYHA class IV heart failure.
- ICD not working properly, or a severe other illness with expected survival under 12 months.
- Pregnancy.
A regiszter feltételei, szó szerint
Mind a 15 feltétel megnézéseKevesebb
Ki vehet részt
- age ≥ 40 years
- carrier of ICD/CRT-D or S-ICD
- episodes of ventricular tachycardia/ventricular fibrillation requiring defibrillator intervention (shock or ATP) which are:; refractory to maximal drug therapy; recurrent (at least 3 episodes in the previous 6 months)
- patients with contraindications to a conventional ablative strategy, in relation to the high risk associated with the procedure due to the severity of the heart disease and/or the presence of comorbidities or patients who have already undergone ablation, in the presence of an arrhythmogenic substrate refractory to or unsuitable for an interventional approach or patients who refuse transcatheter ablative attempts due to high intraoperative risk in relation to the patient's characteristics
- Left ventricular ejection fraction ≥ 20%
Ki nem vehet részt
- previous thoracic radiotherapy (RT) with cardiac involvement
- active myocardial ischemia
- recent cardiac revascularization (< 120 days)
- inability to express informed consent
- hemodynamic instability (cardiogenic shock, NYHA class IV)
- contraindication to radiosurgery (e.g., due to artifacts or other technical reasons)
- lack of patient cooperation in pre-procedural investigations
- ICD malfunction
- severe comorbidity with prognosis < 12 months
- pregnancy
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Ventricular arrhythmias (VAs) are the leading cause of sudden cardiac death (SCD) worldwide. The implantable defibrillator (ICD) increases survival in patients at risk of VA, with data of superiority to antiarrhythmic drugs. Nevertheless, the ICD cannot prevent VAs, and shocks delivered by the device (appropriate and inappropriate) negatively impact patients' quality of life. Transcatheter ablation (TCA) is the percutaneous therapy that can eliminate VAs and prevent any recurrence. TCA is the state of the art for the treatment of drug-unresponsive VAs in patients with structural heart disease, but the prevalence of recurrence remains high (between 30% and 60%). For these reasons, several reports have recently appeared in the literature proposing a new solution for the treatment of VAs in which the use of external-beam body radiotherapy with stereotactic-radiosurgical technique (SBRT) is described. SBRT represents a rapid, noninvasive approach based on the delivery of high radiation doses of photons (25 Gy in a single fraction) to a precise location in cardiac tissue.
A teljes eredeti leírásKevesebb
SBRT has entered the latest 2022 European Society of Cardiology (ESC) guidelines on VAs as a "bailout therapy". Based on preliminary data in the oncology setting, proton therapy could allow further optimization of compliance of these therapeutic doses by preserving even more of the healthy heart part and thus reducing the cardiopulmonary toxicity of radiotherapy outside the ablation target.
The investigators therefore propose an experimental (prospective interventional) study to evaluate the toxicity (primary endpoint) and efficacy (secondary endpoint) of proton radiosurgery for the treatment of VA with an enrollment of 21 patients. The primary endpoint is to evaluate the toxicity of proton radiotherapy in the acute phase (during the first 30 days of the procedure) and at 3, 6 and 12 months. A crucial part of the protocol will be the proper definition of the target to be irradiated, which will require the integration of different non-invasive cardiac imaging methodologies such as CT (Computed Tomography), MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography), coupled with invasive and/or "non-invasive" body surface mapping with multi-electrode electrocardiogram (ECG) so as to obtain a "cardiac image" in which the myocardial scar and the arrhythmogenic region are fused.
A vizsgálat csoportja
- Radiosurgical ablation of a tachyarrhytmogenic substrate with Proton TherapyA vizsgált kezelés
Ablation of the arrhythmogenic substrate with a single dose of 25Gy(RBE) with Proton Therapy after pretreatment diagnostics with CT, MR and electrophysiology for the definition of the arrhytmogenic substrate. Follow-up for 24 months after treatment.
Kezelés: Stereotactic Arrhythmia Radioablation (STAR) with Proton Therapy
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Radiosurgery With proTOns for the Treatment of VEntricular maLignant Tachyarrhytmias (TOVEL Study)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2025. január 27.